Oct. 12, 2026 -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the company to initiate a phase II clinical trial for influenza prevention in general population in the United States. Seasonal vaccination remains central to influenza prevention. However, changes in circulating influenza viruses and va

DTI-117 induced defecation within minutes of intramuscular injection in conscious minipigs, with responder rates rising with dose, and confirmed in a crossover study Pharmacokinetic profile of rapid absorption and fast clearance, with a mean terminal half-life of approximately 3 to 4 minutes, is consistent with a short-acting effect DTI-117 is being evaluated in a NIH-funded randomized, double-blind, placebo-controlled Phase 1 single-ascending-dose study October 13, 2026 – Dignify Therapeutics

-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity -- Oct. 13, 2026 -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the commercial launch of

Mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for pooled placebo. No severe or serious TEAEs, no TEAE-related dose modifications, and no TEAE-related discontinuations among all BMF-650-treated MAD participants. A rapid one-step titration to the target dose of 400 mg QD in Cohort 5 was equally well tolerated with all TEAEs being mild, with nausea and vomiting each reported in only 12.5% of participants, supporting further evaluation of “no titrati

Preclinical study shows 1.5- to 2-hour increase in total sleep time as Company advances toward clinical development and attracts Chris Brearley, M.D., as Chief Medical Officer Oct. 14, 2026 -- Carnyx Therapeutics Ltd. (" Carnyx" or the " Company"), a preclinical-stage biopharmaceutical company developing first-in-class molecular therapeutics for sleep and retinitis pigmentosa, today unveiled CNYX-005, its lead oral sleep candidate, alongside preclinical findings showing increased total sleep ti

Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences” or the “Company”)(SSE: 688321) announced that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for CS43158 tablets, a new molecular entity for the treatment of acute myeloid leukemia (AML), discovered through the company’s AI-enabled Chemical Genomics Platform. CS43158 is a multikinase inhibitor with global patent protection, independently developed by Chipscr

Final independent safety review identifies no findings warranting study changes and recommends that AURORA continue as planned All patients have completed dosing in the global AURORA study evaluating the efficacy and safety of CAL101 in adults with IPF; topline results expected in Q1 2027 Calluna Pharma AS (Calluna), a clinical-stage biotechnology company pioneering first-in-class antibodies for inflammatory and fibrotic diseases, today announced completion of dosing in the Phase 2 AURORA study

Oct. 12, 2026 -- Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, today announced that interim data from the company's Phase 1/2a pediatric clinical trial of RSV vaccine candidate BLB201 will be presented as a late-breaking abstract during the International Society for Vaccines 2026 Annual Congress in Antwerp, Belgi

Bristol Myers Squibb said Monday that the asset at the centre of its $4.1-billion purchase of RayzeBio — an experimental radiopharmaceutical therapy (RPT) dubbed RYZ101 — hit the primary endpoint of a Phase III study for certain patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The ACTION-1 trial enrolled patients with somatostatin receptor-positive GEP-NETs who have progressed following treatment with lutetium-177 (Lu177)-based therapy. Participants were randomised to rec

RESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injury Study builds on functional improvements observed in the placebo-controlled Phase 1b/2a CONNECT SCI study, with FDA alignment on the Phase 3 registrational design Enrollment completion anticipated in the second half of 2027; topline data expected in the first half of 2028 Oct. 12, 2026 -- NervGen (NASDAQ: NGEN), a late-stage clinic